Vutrisiran ATTR Cm denied as non-formulary by Cigna?
Non-formulary doesn't mean uncoverable. Most plans have a formulary-exception process: the appeal needs to show the formulary alternatives are inappropriate for your specific clinical situation.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for vutrisiran attr cm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on Vutrisiran ATTR Cm
## Why Cigna Denies Vutrisiran (ATTR-CM) as Non-Formulary — and How to Appeal
Vutrisiran (Amvuttra) is an FDA-approved therapy for transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). A non-formulary denial means vutrisiran is not included on Cigna's drug benefit list for your specific plan, or is placed at a tier that makes it inaccessible. Non-formulary denials are appealed through a formulary exception process, which is a well-established and frequently granted pathway — particularly for serious conditions with limited therapeutic alternatives.
## Why This Denial Is Appealable
Under ACA §2719 and applicable federal regulations, insurers must have an exceptions process for non-formulary drugs when a covered drug is not clinically appropriate for a specific patient. Under ERISA §503, employer-sponsored plans must provide a full-and-fair review of any adverse benefit determination, including formulary decisions. After a final internal denial, independent external review is available, typically within approximately four months. Given the progressive and life-threatening nature of ATTR-CM, expedited review (often resolved within 72 hours) is available when delay would seriously jeopardize your health.
For a condition as serious as ATTR-CM, the formulary-exception bar is relatively low: your cardiologist must document that formulary alternatives are clinically inappropriate for your situation. Because ATTR-CM has a limited set of approved therapies, this is often a straightforward showing.
## What to Gather
- Diagnosis confirmation: Cardiologist records, nuclear imaging or biopsy confirming ATTR-CM, genetic testing if applicable.
- Formulary alternatives review: A letter from your cardiologist identifying any formulary alternatives Cigna might suggest, and explaining — for each one — why it is clinically inappropriate, insufficient, or not interchangeable for your specific case.
- FDA prescribing label: Obtain the current full prescribing information for vutrisiran directly from the FDA label, confirming the approved ATTR-CM indication.
- Prescriber medical-necessity letter: A letter from your cardiologist requesting a formulary exception, citing the FDA approval, the clinical necessity for this specific agent, and any relevant ACC/AHA guideline support.
- Cigna exception request form: Most plans have a standard formulary-exception form — ask your cardiologist's office to submit it simultaneously with the appeal.
## Criteria-Mapping Structure
Address each of Cigna's formulary-exception criteria:
> Cigna exception criterion: [paste verbatim from policy or exception form] > Supporting evidence: [diagnosis confirmation, prescriber rationale, or chart fact]
## Timeline
File your formulary exception request and internal appeal simultaneously, as soon as you receive the denial. Confirm the exact appeal deadline in your denial letter. After a final internal denial, file for external review promptly to preserve your rights within the approximately four-month window.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →